Further Notifications

Here you find all press releases and further notifications, as well as all events of Fraunhofer ITMP.

Press Release/News / 6.5.2022

Opening of the Fraunhofer ITMP laboratories at Roche in Penzberg


On May 6, 2022, the laboratories of the Fraunhofer ITMP site for immunology, infection and pandemic research in Penzberg/Munich were officially opened. The aim of the on-site research is to identify and characterize pandemic pathogens, develop new diagnostics and therapies, and better understand the role of the immune system in infectious diseases. Until the completion of their own building, the researchers will start their work in rented rooms on the campus of Roche's biotechnology center in Penzberg. 

Press Release / 5.5.2022

AIOLOS launches development of an early detection platform for epidemics


The Franco-German AIOLOS project (Artificial Intelligence Tools for Outbreak Detection and Response) has received approval to develop a digital platform designed to allow for early detection of new respiratory pathogens epidemics, monitor their spread and inform decisions on appropriate counter measures.

Sanofi in France and the Fraunhofer Institutes SCAI and ITMP in Germany lead the consortium, which includes four other French and German partners.

News / 8.4.2022

Fraunhofer ITMP Spin-Off "Phialogics" Wins Sanofi "Golden Tickets" Competition


"Phialogics", the barely six-month-old spin-off of the Frankfurt site of the Fraunhofer ITMP, wins Sanofi's "Golden Tickets" competition. This enables the Fraunhofer spin-off to stay free of charge for one year at BioLabs in Heidelberg, which is becoming a hotspot for start-ups based on a concept imported from the USA.

"" reports on Phialogics and its success in the "Start-up of the Week" section.

News / 1.4.2022

After the virus is before the virus - Interview on the new Fraunhofer ITMP site in Munich/Penzberg


In mid-April, the first scientists of the Fraunhofer ITMP in Penzberg start work in rented laboratory space at Roche. The new center for Immunology, Infection and Pandemic Research is expected to be ready in 2-3 years. Süddeutsche Zeitung interviewed Gerd Geißlinger, head of the institute, and Michael Hoelscher, head of the Munich/Penzberg site, about the purpose of the future center: A conversation about new viruses and why diseases can be stopped with "4D".

Press Release / 20.1.2022

SARS-CoV-2 infection route via brain vessels identified


Neurological complications associated with COVID-19 occur frequently. Although the SARS-CoV-2 virus has already been detected in the brain tissue of patients, its routes of entry and the resulting consequences are not well understood. A team of researchers from Fraunhofer ITMP and the University Medical Center Hamburg-Eppendorf (UKE) has now shown that cells of the blood-brain barrier (BBB) can be infected in vitro by the SARS-CoV-2 pathogen and that this can be attenuated pharmacologically.

Press Release / 17.12.2021

New drug shows promise for the treatment of chronic spontaneous urticaria


Patients with chronic spontaneous urticaria are severely impaired in their quality of life. Unfortunately, standard therapy with antihistamines is not efficacious in many affected patients. However, these patients can now have hope. A new clinical trial with the participation of Fraunhofer ITMP in Berlin shows promising results for the efficacy of a new drug.

Research Divisions

Fraunhofer ITMP is organized in 3 cross-site research divisions.


Drug Discovery


From target to screening to lead optimization and formulation.


Preclinical Research


Translational cycles and OMICs analyses for characterization of biological mechanisms and novel targets.


Clinical Research


From „Proof-of-Concept“ to the characterization of established products: “Quality by Design” for successful translation of innovative ideas.

Innovation Areas

Fraunhofer ITMP is optimally interconnected internally as well as externally with other Fraunhofer institutes, universities and industry via the innovation areas. This is the prerequisite for transdisciplinary and flexible cooperation in the areas of new technologies, disease and treatment concepts.

Institute Locations


Locations of Fraunhofer ITMP


Fraunhofer ITMP, with its headquarters in Frankfurt am Main, currently has four additional institute locations in Hamburg, Göttingen, Berlin and Penzberg/Munich.


Headquarters of Fraunhofer ITMP

Frankfurt am Main


The site has strong expertise in pharmacology and clinical trials in immune-mediated diseases and pain. 


Discovery Research ScreeningPort



The site has strong expertise in high-throughput drug discovery (in silico, in vitro screening and drug repurposing) as well as a broad offering in "medical data science".


Translational Neuroinflammation and Automated Microscopy TNM


The site has strong expertise in high- and super-resolution microscopy techniques; as well as neuroinflammation and degenerative diseases.


Immunology and Allergology IA


The site has strong expertise in dermatology, allergology, and immunological mast cell-mediated inflammatory diseases of the skin.


Immunology, Infection and Pandemic Research IIP


The site has strong expertise in developing interventions to address the outbreak of new and spread of existing infectious diseases.